Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Krystal Biotech (KRYS)

Krystal Biotech Q2 net income $15.6M vs loss a year ago; revenue $70.3M

Positive Impact 3 of 5 earnings Written later

Krystal Biotech reported second-quarter 2024 product revenue of $70.3 million from VYJUVEK, up 55.3% from the first quarter, and net income of $15.6 million ($0.53 per diluted share), compared with a net loss of $33.2 million a year earlier. Results include a $12.5 million litigation settlement charge, and the company kept its 2024 R&D and SG&A expense guidance of $150 million to $175 million (non-GAAP, excluding stock-based compensation) unchanged.

Key points

  • Q2 2024 product revenue, net: $70.3 million, up 55.3% from Q1 2024; gross margin 91%
  • Q2 2024 net income: $15.6 million, or $0.53 per diluted share, versus a net loss of $33.2 million in Q2 2023
  • Q2 2024 included a $12.5 million litigation settlement expense
  • Cash, cash equivalents and investments: $628.9 million as of June 30, 2024; 2024 R&D and SG&A guidance unchanged

The filing

CompanyKrystal Biotech (KRYS)
Form8-K, current report
Filed with the SECAug 5, 2024, 8:03 AM ET
Accession number0001711279-24-000038

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.